The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy  Younak Choi, MD, Tae-Yong Kim, MD, Kyung-hun Lee, MD, Sae-Won Han, MD, PhD, Do-Youn Oh, MD, PhD, Seock-Ah Im, MD, PhD, Tae-You Kim, MD, PhD, Yung-Jue Bang, MD, PhD  Journal of Pain and Symptom Management  Volume 48, Issue 1, Pages 13-25 (July 2014) DOI: 10.1016/j.jpainsymman.2013.08.017 Copyright © 2014 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 1 Median OS by BMI group. a) Median OS by BMI-D: BMI <18.5 (7.2 months, P = 0.066); BMI 18.5–19.9 (8.4 months, P = 0.183); BMI 20.0–22.4 (7.2 months, P = 0.093); BMI 22.5–25.0 (9.9 months, reference); and BMI ≥25.0 (6.7 months, P = 0.335). b) Median OS by precancer BMI: BMI <18.5 (7.4 months, P = 0.550); BMI 18.5–19.9 (8.2 months, P = 0.917); BMI 20.0–22.4 (7.7 months, P = 0.089); BMI 22.5–25.0 (8.1 months, reference); and BMI ≥25.0 (8.4 months, P = 0.728). Journal of Pain and Symptom Management 2014 48, 13-25DOI: (10.1016/j.jpainsymman.2013.08.017) Copyright © 2014 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 2 Median OS by weight loss. a) Median OS by weight loss at diagnosis, BMI change ≥1 (HR, 1.300; 95% CI 1.060–1.591; P = 0.012). b) Median OS by weight loss during first-line chemotherapy; no weight loss (11.0 months, reference); BMI change <1 (7.7 months, P = 0.018); BMI change 1–1.99, (7.8 months, P = 0.002); and BMI change ≥2 (8.9 months, P = 0.027). c) Median OS by weight loss during first-line chemotherapy, BMI change ≥1 (HR, 1.367% CI 1.078–1.734; P = 0.010). Journal of Pain and Symptom Management 2014 48, 13-25DOI: (10.1016/j.jpainsymman.2013.08.017) Copyright © 2014 U.S. Cancer Pain Relief Committee Terms and Conditions